Hemophilia A is a congenital bleeding disorder due to deficiency ofFVIII. Hemophilia occurs in mild, moderate, and severe forms.It is an x-linked recessive disorder affecting males more than females.Hemophiliacs are treated with exogenous FVIII to control bleedingepisodes. Consequently, hemophiliacs are prone to develop FVIIIinhibitors as a complication of therapy with external FVIII.In our study, we screened thirty hemophilia A patients regularlyfollowing-up in the National Blood Transfusion Center, and in PediatricHematology, in Cairo University for FVIII inhibitors.10% of ourpatients were inhibitor positive.